

Supporting Information

Transposition of Acrylate Moiety in TMSOTf-Mediated Reaction of Alkynyl Vinylogous Carbonates Gives Heterocyclic Dienes

Santosh J. Gharpure, Dipak J. Fartade, Krishna S. Gupta, Raj K. Patel

Department of Chemistry, Indian Institute of Technology Bombay, Powai, Mumbai

400076

India. Fax: +91-22-2576 7152; Tel: +91-22-2576 7171; E-mail: sjgharpure@iitb.ac.in

Table of Contents


- General.....S2
- Optimization table.....S3
- Experimental and Characterization of compounds.....S4-S25
- Spectra and X-Ray crystallographic analysis.....S26-S62

General experimental:

Melting points are recorded using dbk programmable melting point apparatus in capillary tubes and are uncorrected. IR spectra were recorded on Nicolet 6700 spectrophotometer. ^1H (400 MHz) and ^{13}C (100 MHz) NMR spectra were recorded on Bruker Avance 400 spectrometer. ^1H (500 MHz) and ^{13}C (125 MHz) NMR spectra were recorded on Bruker Avance 500 spectrometer. The chemical shifts (δ ppm) and coupling constants (Hz) are reported in the standard fashion with reference to either internal tetramethylsilane or residual CHCl_3 (7.26 ppm for ^1H) or the central line (77.16 ppm) of CDCl_3 (for ^{13}C). In the ^{13}C NMR spectra, the nature of the carbons (C, CH, CH_2 or CH_3) was determined by recording the DEPT-135 experiment and is given in parentheses.

High resolution mass measurements were carried out using Maxis impact (brucker) instrument using direct inlet mode. X-ray diffraction studies were carried out using Bruker Single Crystal Kappa Apex II. Analytical thin-layer chromatographies (TLC) were performed on glass plates (7.5×2.5 and 9×5.0 cm) coated with Merck or Acme's silica gel G containing 13% calcium sulfate as binder or on pre-coated 0.2 mm thick Merck 60 F₂₄₅ silica plates and various combinations of ethyl acetate and Petroleum ether were used as eluent. Visualization of spots was accomplished by either exposure to iodine vapour or KMnO_4 stain or vanillin strain. All small-scale dry reactions were carried out using standard syringe septum technique. Dry dichloromethane was prepared by refluxing over anhydrous P_2O_5 and distillation on to calcium hydride. Dry DMF was prepared by stirring on CaH and distillation on to molecular sevies. $\text{BF}_3\cdot\text{OEt}_2$, $\text{Cu}(\text{OTf})_2$, TMSOTf, TfOH, AgOTf, CuI, Et_3SiH and BBr_3 (1M heptane) were obtained from Aldrich. All other Lewis/Bronsted acids, Iodobenzene, NaH (60% dispersion in mineral oil), benzyl bromide, cyclohexene oxide, cyclopentene oxide, propargyl bromide (80% in toluene), Mg turning, DMP, $[\text{Pd}(\text{PPh}_3)_2]\text{Cl}_2$, $\text{Pd}(\text{OAc})_2$, PPh_3 , aryl iodides are commercial reagents and were used as such without further purification. All other internal alkynyl vinylogous carbonate were prepared using literature established protocol.

Table S1. Optimization table for synthesis of 1,4-oxazepines




| Entry | Acids ^a (equiv) | Additives | Time (h) | Yield (%) ^{b,d} (3a) | Yield (%) ^b (4a) |
|-------|---------------------------------------|-----------------------------------|----------|-------------------------------------------|-----------------------------------------|
| 1 | TMSOTf (1.0) | - | 0.5 | 35 | 31 |
| 2 | TMSOTf (1.0) | 4 Å MS | 0.5 | 40 | 27 |
| 3 | TMSOTf (1.0) | MgSO ₄ | 0.5 | 45 | 26 |
| 4 | In(OTf) ₃ (0.2) | MgSO ₄ | 2 | - | 86 |
| 5 | Sc(OTf) ₃ (0.2) | MgSO ₄ | 2 | - | 88 |
| 6 | Ag(OTf) (1) | MgSO ₄ | 12 | - | 82 |
| 7 | BF ₃ ·OEt ₂ (1) | MgSO ₄ | 2 | Trace | 77 |
| 8 | TfOH (1) | MgSO ₄ | 0.5 | - | 86 |
| 9 | TMSOTf (2) | MgSO ₄ | 0.5 | 54 (50) ^c | 20 (14) ^c |
| 10 | TMSOTf (3) | MgSO ₄ | 0.5 | 68 (65) ^c | 11 (6) ^c |
| 11 | TMSOTf (4) | MgSO ₄ | 0.5 | 65 | 9 |
| 12 | TMSOTf (5) | MgSO ₄ | 0.5 | 60 | 31 |
| 13 | TMSOTf (5) | Na ₂ SO ₄ | 0.5 | 65 | 14 |
| 14 | TMSOTf (3) | Ca(SO ₄) ₂ | 0.5 | 42 | 17 |
| 15 | TMSOTf (3) | CaH ₂ | 0.5 | 23 | - |
| 16 | TMSOTf (3) | CaCl ₂ | 0.5 | 31 | 11 |
| 17 | TiCl ₄ ^e (1) | 1 | 0.5 | - | 76 |

^aall reactions were carried out using **1** (0.15 mmol), with slow addition of acids at 0 °C in dry solvent (3 ml) for 0.5-12h. ^bNMR yield using 1,3,5-trimethoxybenzene as an internal standard. ^cYield of isolated product after purification by silica gel column chromatography. ^dE/Z selectivity was measured by ¹H NMR on crude reaction mixture and was found to be ≥19:1. ^ewithout MgSO₄.

Experimental Procedure

Representative experimental procedure for synthesis of substituted 1,4-oxazepine and dihydropyran derivatives:



To a magnetically stirred suspension of activated magnesium sulfate (40 equiv) and vinylogous carbonate in dry CH_2Cl_2 (5 mL), TMSOTf was added dropwise at 0 °C. Reaction was monitored by TLC, quenched with saturated aq. solution of NaHCO_3 upon completion, extracted with CH_2Cl_2 (3×5 mL) and dried over anhydrous Na_2SO_4 . Evaporation of the solvent and purification of the residue over a silica gel column using EtOAc-petroleum ether as eluent furnished 1,4-oxazepines.

7.4 General procedure for synthesis of 1,4-oxazepines:

ethyl(E)-3-((5aS,9aS*)-2-phenyl-5-tosyl-4,5,5a,6,7,8,9,9a*

octahydrobenzo[b][1,4]oxazepin-3-yl)acrylate 3a:


To a magnetically stirred suspension of activated magnesium sulfate (0.730 gm, 6.04 mmol) and vinylogous carbonate **1a** (73.0 mg, 0.151 mmol) in dry CH_2Cl_2 (5 mL), TMSOTf (83 μL , 0.456 mmol) was added dropwise at 0 °C. Reaction was monitored by TLC, quenched with saturated aq. solution of NaHCO_3 upon completion, extracted with CH_2Cl_2 (3×5 mL) and dried over anhydrous Na_2SO_4 . Evaporation of the solvent and purification of the residue over a silica gel column using EtOAc-petroleum ether as eluent furnished 1,4-oxazepines **3a** (46.4 mg, 65%).

Physical appearance: Yellow solid.

M.P: 128-130 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

IR (neat): 2933, 2860, 1708, 1600, 1586, 1447, 1306, 1267, 1093, 814, 756, 577 cm^{-1} .



¹H NMR (400 MHz, CDCl_3): δ 7.64 (d, $J = 8.0$ Hz, 2H), 7.32 (t, $J = 7.2$ Hz, 1H), 7.23 (t, $J = 7.2$ Hz, 2H), 7.16 (d, $J = 16.0$ Hz, 1H), 7.07 (d, $J = 8.0$ Hz, 2H), 6.84 (d, $J = 7.5$ Hz, 2H), 5.77 (d, $J = 16.0$ Hz, 1H), 4.73 (d, $J = 18.8$ Hz, 1H), 4.15-4.10 (m, 4H), 3.95 (td, $J = 10.8, 4.0$ Hz, 1H), 2.23-2.18 (m, 4H), 1.86 (d, $J = 13.2$ Hz, 1H), 1.80 (d, $J = 12.8$ Hz, 1H), 1.68-1.63 (m, 4H), 1.24 (t, $J = 7.2$ Hz, 4H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.6 (C), 164.4 (C), 144.0 (CH), 143.1 (C), 137.9 (C), 134.2 (C), 130.3 (2 × CH), 130.2 (CH), 129.6 (2 × CH), 127.8 (2 × CH), 127.0 (2 × CH), 113.0 (CH), 109.1 (C), 83.3 (CH), 62.8 (CH), 60.2 (CH₂), 41.0 (CH₂), 32.8 (CH₂), 32.7 (CH₂), 24.4 (CH₂), 24.3 (CH₂), 21.4 (CH₃), 14.4 (CH₃).


HRMS (ESI, M+Na⁺): m/z calcd. For C₂₇H₃₁NNaO₅S 504.1815, found 504.1814.

N-((1*S,2*S**)-2-hydroxycyclohexyl)-4-methyl-N-(3-phenylprop-2-yn-1-yl)benzenesulfonamide 4a:**

Physical appearance: Brown solid.

M.P: 86-88 °C.

R_f: 0.5 (2:8, EtOAc: Petroleum ether).



IR (neat): 3548, 2936, 2862, 2126, 1334, 1163, 1091, 1073, 1042, 885, 768 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.85 (dd, *J* = 8.4, 1.6 Hz, 2H), 7.32-7.25 (m, 3H), 7.23-7.18 (m, 4H), 4.45 (d, *J* = 18.8 Hz, 1H), 4.28 (d, *J* = 18.8 Hz, 1H), 3.66-3.64 (m, 2H), 2.47 (s, 1H), 2.35 (s, 3H), 2.12 (d, *J* = 12 Hz, 1H), 1.73-1.67 (m, 3H), 1.58-1.48 (m, 1H), 1.35-1.18 (m, 3H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 143.6 (C), 137.8 (C), 131.6 (2 × CH), 129.6 (2 × CH), 128.8 (CH), 128.4 (2 × CH), 127.7 (2 × CH), 122.0 (C), 84.9 (C), 84.8 (C), 70.1 (CH), 64.4 (CH), 33.9 (CH₂), 33.1 (CH₂), 29.5 (CH₂), 25.4 (CH₂), 24.2 (CH₂), 21.6 (CH₃).

HRMS (ESI, M+Na⁺): m/z calcd. For C₂₂H₂₅NNaO₃S 406.1447 found 406.1449.


ethyl(*E*)-3-((5*a*S*,9*a*S*)-2-(*p*-tolyl)-5-tosyl-4,5,5*a*,6,7,8,9,9*a*-octahydrobenzo[*b*][1,4]oxazepin-3-yl)acrylate 3b:

To a magnetically stirred suspension of activated magnesium sulfate (0.651 gm, 5.408 mmol) and vinylogous carbonate **1b** (67.0 mg, 0.135 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (74 μL, 0.405 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3b** (49.0 mg, 73%).

Physical appearance: White solid.

M.P: 244-246 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).



IR (neat): 2940, 1704, 1604, 1585, 1267, 1157, 1038, 760 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, *J* = 8.0 Hz, 2H), 7.17 (d, *J* = 16.0 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 2H), 7.03 (d, *J* = 8.0 Hz, 2H), 6.73 (d, *J* = 8.0 Hz, 2H), 5.74 (d, *J*

= 16.0 Hz, 1H), 4.71 (d, J = 18.4 Hz, 1H), 4.17-4.08 (m, 4H), 3.95 (td, J = 10.8, 3.6 Hz, 1H), 2.32 (s, 3H), 2.22-2.17 (m, 4H), 1.86 (d, J = 12.8 Hz, 1H), 1.80 (d, J = 13.2 Hz, 1H), 1.67-1.31 (m, 4H), 1.25 (t, J = 7.2 Hz, 4H).

^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 167.7 (C), 164.7 (C), 144.4 (CH), 143.1 (C), 140.4 (C), 137.9 (C), 131.4 (C), 130.2 ($2 \times$ CH), 129.6 ($2 \times$ CH), 128.5 ($2 \times$ CH), 127.0 ($2 \times$ CH), 112.4 (CH), 108.6 (C), 83.1 (CH), 62.8 (CH), 60.1 (CH_2), 41.0 (CH_2), 32.8 (CH_2), 32.7 (CH_2), 24.4 (CH_2), 24.3 (CH_2), 21.5 (CH_3), 21.4 (CH_3), 14.4 (CH_3).

HRMS (ESI, M+ H^+): m/z calcd. For $\text{C}_{28}\text{H}_{34}\text{NO}_5\text{S}$ 496.2152, found 496.2152.


ethyl(*E*)-3-((5a*S,9a*S**)-2-(4-methoxyphenyl)-5-tosyl-4,5,5a,6,7,8,9,9a-octahydrobenzo[*b*][1,4]oxazepin-3-yl)acrylate 3c:**

To a magnetically stirred suspension of activated magnesium sulfate (0.707 gm, 5.87 mmol) and vinylogous carbonate **1c** (75.0 mg, 0.146 mmol) in dry CH_2Cl_2 (5 mL), TMSOTf (80 μL , 0.439 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3c** (25.0 mg, 34%).

Physical appearance: White solid.

M.P: 210-212 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).



IR (neat): 2925, 2852, 1708, 1599, 1462, 1306, 1253, 1170, 755 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ 7.64 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 15.6 Hz, 1H), 7.07 (d, J = 8.0 Hz, 2H), 6.82-6.74 (m, 4H), 5.74 (d, J = 16.0 Hz, 1H), 4.71 (d, J = 18.8 Hz, 1H), 4.17-4.07 (m, 4H), 3.95 (td, J = 11.2, 4.4 Hz, 1H), 3.80 (s, 3H), 2.22 (s, 3H), 1.87 (d, J = 12.8 Hz, 1H), 1.81 (d, J = 13.2 Hz, 1H), 1.68-1.41 (m, 6H), 1.26 (t, J = 7.2 Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 167.8 (C), 164.5 (C), 161.2 (C), 144.5 (CH), 143.0 (C), 138.0 (C), 131.9 ($2 \times$ CH), 129.6 ($2 \times$ CH), 127.0 ($2 \times$ CH), 126.6 (C), 113.3 ($2 \times$ CH), 112.2 (CH), 108.1 (C), 83.0 (CH), 62.8 (CH), 60.2 (CH_2), 55.5 (CH_3), 41.1 (CH_2), 32.8 (CH_2), 32.7 (CH_2), 24.4 ($2 \times$ CH_2), 21.5 (CH_3), 14.5 (CH_3).

HRMS (ESI, M+ H^+): m/z calcd. For $\text{C}_{28}\text{H}_{34}\text{NO}_6\text{S}$ 512.2115, found 512.2115.

ethyl(E)-3-((5aS,9aS*)-2-(4-chlorophenyl)-5-tosyl-4,5,5a,6,7,8,9,9a-octahydrobenzo[b][1,4]oxazepin-3-yl)acrylate 3d:*


To a magnetically stirred suspension of activated magnesium sulfate (0.792 gm, 6.583 mmol) and vinylogous carbonate **1d** (85.0 mg, 0.164 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (89 μ L, 0.494 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3d** (45.0 mg, 53%).

Physical appearance: Brown solid.

M.P: 190-192 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

IR (neat): 2939, 1706, 1598, 1584, 1304, 1265, 1176, 1038, 759 cm⁻¹.



¹H NMR (400 MHz, CDCl₃): δ 7.62 (d, *J* = 8.4 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 2H), 7.11-7.06 (m, 3H), 6.77 (d, *J* = 8.8 Hz, 2H), 5.78 (d, *J* = 15.6 Hz, 1H), 4.71 (d, *J* = 18.8 Hz, 1H), 4.16-4.08 (m, 4H), 3.95 (td, *J* = 10.8, 3.6 Hz, 1H), 2.22-2.16 (m, 5H), 1.86 (d, *J* = 13.6 Hz, 1H), 1.80 (d, *J* = 12.8 Hz, 1H), 1.63-1.41 (m, 3H), 1.34-1.20 (m, 4H).


¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.4 (C), 162.9 (C), 143.3 (CH), 143.1 (C), 137.9 (C), 136.2 (C), 132.7 (C), 131.5 (2 × CH), 129.6 (2 × CH), 128.0 (2 × CH), 127.0 (2 × CH), 113.5 (CH), 109.5 (C), 83.4 (CH), 62.7 (CH), 60.3 (CH₂), 40.9 (CH₂), 32.7 (CH₂), 32.6 (CH₂), 24.3 (CH₂), 24.2 (CH₂), 21.4 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₇H₃₁ClNO₅S 516.1623, found 516.1622.

ethyl(E)-3-((5aS,9aS*)-2-phenyl-5-tosyl-4,5,5a,6,7,8,9,9a*

octahydrobenzo[b][1,4]oxazepin-3-yl)acrylate 3f:

To a magnetically stirred suspension of activated magnesium sulfate (0.737 gm, 6.12 mmol) and vinylogous carbonate **1f** (78.0 mg, 0.153 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (84 μ L, 0.459 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3f** (40.0 mg, 51%).



Physical appearance: Sticky solid.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

IR (neat): 2936, 1708, 1604, 1585, 1250, 1170, 1044, 758 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.66 (d, *J* = 8.4 Hz, 2H), 7.18-7.12 (m, 3H), 6.94 (s, 1H), 6.45 (s, 2H), 5.74 (d, *J* = 16.0 Hz, 1H), 4.74 (d, *J* = 18.4 Hz, 1H), 4.19-4.08 (m, 4H), 3.94 (td, *J* = 10.4, 3.6 Hz, 1H), 2.25 (s, 6H), 2.23 (s, 3H), 1.87 (d, *J* = 13.2 Hz, 1H), 1.81 (d, *J* = 13.2 Hz, 1H), 1.67-1.39 (m, 4H), 1.33-1.23 (m, 5H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.5 (C), 164.9 (C), 144.3 (CH), 142.9 (C), 138.0 (C), 137.3 (2 × C), 134.2 (C), 131.8 (CH), 129.6 (2 × CH), 128.0 (2 × CH), 127.0 (2 × CH), 112.6 (CH), 109.0 (C), 83.3 (CH), 62.8 (CH), 60.1 (CH₂), 41.0 (CH₂), 32.7 (2 × CH₂), 24.4 (CH₂), 24.3 (CH₂), 21.5 (CH₃), 21.3 (2 × CH₃), 14.4 (CH₃).

HRMS (ESI, M+H⁺): m/z calcd. For C₂₉H₃₆NO₅S 510.2333, found 510.2332.

(Note: Compound 6g shows rotamers and data written for the major isomer.)


ethyl(E)-3-((5aS*,9aS*)-2-(2-methoxyphenyl)-5-tosyl-4,5,5a,6,7,8,9,9a-octahydrobenzo[b][1,4]oxazepin-3-yl)acrylate 3g:

To a magnetically stirred suspension of activated magnesium sulfate (0.97 gm, 8.05 mmol) and vinylogous carbonate **1g** (103.0 mg, 0.201 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (111 μL, 0.604 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3g** (57.0 mg, 55%).

Physical appearance: Yellow solid.

M.P: 156-158 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).



IR (neat): 2931, 2858, 1707, 1605, 1590, 1262, 1177, 1034, 756, 666 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, *J* = 8.4 Hz, 2H), 7.29-7.26 (m, 1H), 7.21 (d, *J* = 7.6 Hz, 2H), 6.93 (d, *J* = 16.0 Hz, 1H), 6.82 (d, *J* = 8.4 Hz, 1H), 6.73 (t, *J* = 6.8 Hz, 1H), 6.0 (s, 1H), 5.72 (d, *J* = 16.0 Hz, 1H), 4.72 (d, *J* = 18.4 Hz, 1H), 4.17-4.08 (m, 4H), 3.94 (s, 1H), 3.74 (s, 3H), 2.36 (s, 3H), 2.24 (d, *J* = 9.6 Hz, 1H), 2.15 (d, *J* = 8.4 Hz, 1H), 1.82 (t, *J* = 14 Hz, 2H), 1.64-1.28 (m, 4H), 1.23 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.5 (C), 163.6 (C), 158.0 (C), 143.9 (C), 143.2 (CH), 138.3 (C), 131.8 (CH), 131.4 (CH), 129.7 (2 × CH), 127.2 (2 × CH), 123.5 (C), 119.8 (CH), 112.6 (CH), 111.4 (CH), 111.1 (C), 83.5 (CH), 63.2 (CH), 60.2 (CH₂), 55.4 (CH₃), 40.9 (CH₂), 32.6 (CH₂), 32.5 (CH₂), 24.5 (CH₂), 24.4 (CH₂), 21.5 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+H⁺): m/z calcd. For C₂₈H₃₄NO₆S 512.2135, found 512.2134.

ethyl(S,E)-3-(3-methyl-7-(p-tolyl)-4-tosyl-2,3,4,5-tetrahydro-1,4-oxazepin-6-yl)acrylate 3h:

To a magnetically stirred suspension of activated magnesium sulfate (1.056 gm, 8.78 mmol) and vinylogous carbonate **1h** (100.0 mg, 0.219 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (119 μ L, 0.658 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3h** (42.0 mg, 42%).


Physical appearance: Pale yellow solid.

M.P: 73-75 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

[α]_D²⁵: -501.805 (c 0.345, CHCl₃).

IR (neat): 3019, 2996, 1701, 1608, 1364, 1216, 1130, 759, 669 cm⁻¹.



¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J* = 8.8 Hz, 2H), 7.19 (d, *J* = 16.0 Hz, 1H), 7.05 (dd, *J* = 8.0, 3.2 Hz, 4H), 6.78 (d, *J* = 8.0 Hz, 2H), 5.78 (d, *J* = 16.0 Hz, 1H), 4.70 (d, *J* = 18.8 Hz, 1H), 4.59-4.53 (m, 1H), 4.26 (dd, *J* = 12.8, 5.6 Hz, 1H), 4.16-4.04 (m, 4H), 2.32 (s, 3H), 2.20 (s, 3H), 1.28-1.23 (m, 6H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.6 (C), 165.1 (C), 144.0 (CH), 143.1 (C), 140.5 (C), 137.8 (C), 131.2 (C), 130.2 (2 × CH), 129.5 (2 × CH), 128.5 (2 × CH), 127.0 (2 × CH), 113.0 (CH), 108.9 (C), 74.9 (CH₂), 60.2 (CH₂), 53.9 (CH), 39.6 (CH₂), 21.4 (2 × CH₃), 16.6 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+H⁺): m/z calcd. For C₂₅H₃₀NO₅S 456.1862, found 456.1861.

ethyl(S,E)-3-(3-isobutyl-7-(p-tolyl)-4-tosyl-2,3,4,5-tetrahydro-1,4-oxazepin-6-yl)acrylate 3i:


To a magnetically stirred suspension of activated magnesium sulfate (1.639 gm, 13.66 mmol) and vinylogous carbonate **1i** (170.0 mg, 0.341 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (185 μ L, 1.025 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3i** (80.0 mg, 43 %).

Physical appearance: Pale yellow solid.

M.P: 80-82 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

[α]_D²⁵: -507.720 (c 0.605, CHCl₃).



IR (neat): 2955, 1708, 1601, 1466, 1311, 1261, 1174, 1095, 1037, 824, 670 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 16.0 Hz, 1H), 7.05-7.00 (m, 4H), 6.73 (d, *J* = 6.8 Hz, 2H), 5.77 (d, *J* = 16.0 Hz, 1H), 4.67 (d, *J* = 18.8 Hz, 1H), 4.56-4.48 (m, 1H), 4.33 (dd, *J* = 12.4, 5.6 Hz, 1H), 4.14 (q, *J* = 7.2 Hz, 2H), 4.04 (d, *J* = 18.8 Hz, 1H), 3.99 (t, *J* = 12.0 Hz, 1H), 2.32 (s, 3H), 2.16 (s, 3H), 1.89-1.79 (m, 1H), 1.56-1.49 (m, 1H), 1.25 (t, *J* = 7.2 Hz, 4H), 1.01 (d, *J* = 6.4 Hz, 3H), 1.00 (d, *J* = 6.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.5 (C), 165.2 (C), 143.9 (CH), 143.0 (C), 140.4 (C), 137.7 (C), 131.1 (C), 130.1 (2 × CH), 129.4 (2 × CH), 128.4 (2 × CH), 127.2 (2 × CH), 113.1 (CH), 109.0 (C), 74.7 (CH₂), 60.1 (CH₂), 56.2 (CH), 40.1 (2 × CH₂), 24.7 (CH), 23.0 (CH₃), 22.6 (CH₃), 21.4 (CH₃), 21.3 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₈H₃₆NO₅S 498.2342, found 498.2341.

ethyl(S,E)-3-(7-(4-chlorophenyl)-3-isobutyl-4-tosyl-2,3,4,5-tetrahydro-1,4-oxazepin-6-yl)acrylate 3j:

To a magnetically stirred suspension of activated magnesium sulfate (1.85 gm, 15.44 mmol) and vinylogous carbonate **1j** (200.0 mg, 0.386 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (209 μL, 1.158 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3j** (85.0 mg, 43%).


Physical appearance: Pale yellow solid.

M.P: 78-80 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

[*a*]D²⁵: -478.035 (c 0.525, CHCl₃).

IR (neat): 2956, 1702, 1601, 1489, 1339, 1259, 1155, 1095, 758, 671 cm⁻¹.



¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J* = 8.4 Hz, 2H), 7.27-7.20 (m, 2H), 7.11 (d, *J* = 16 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 2H), 6.80-6.76 (m, 2H), 5.82 (d, *J* = 16.0 Hz, 1H), 4.69 (d, *J* = 18.8 Hz, 1H), 4.58-4.51 (m, 1H), 4.35 (dd, *J* = 12.8, 6.0 Hz, 1H), 4.16 (q, *J* = 6.8 Hz, 2H), 4.10 (d, *J* = 18.4 Hz, 1H), 4.00 (t, *J* = 12.0 Hz, 1H), 2.19 (s, 3H), 1.90-1.80 (m, 1H), 1.58-1.50 (m, 1H), 1.28-1.22 (m, 4H), 1.02 (d, *J* = 6.4 Hz, 3H), 1.01 (d, *J* = 6.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.3 (C), 163.4 (C), 143.1 (C), 142.9 (CH), 137.8 (C), 136.2 (C), 132.4 (C), 131.4 (2 × CH), 129.4 (2 × CH), 127.9 (2 ×

CH), 127.2 (2 × CH), 114.2 (CH), 110.0 (C), 74.9 (CH₂), 60.3 (CH₂), 56.2 (CH), 40.1 (CH₂), 40.0 (CH₂), 24.7 (CH), 23.0 (CH₃), 22.6 (CH₃), 21.3 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₇H₃₃ClNO₅S 518.1772, found 518.1771.

ethyl(S,E)-3-(3-isopropyl-7-phenyl-4-tosyl-2,3,4,5-tetrahydro-1,4-oxazepin-6-yl)acrylate 3k:


To a magnetically stirred suspension of activated magnesium sulfate (0.697 gm, 5.79 mmol) and vinylogous carbonate **1k** (68.0 mg, 0.145 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (79 μL, 0.434 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3k** (31.0 mg, 46%).

Physical appearance: Sticky solid.

[α]_D²⁵: -76.407 (c 0.155, CHCl₃).

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

IR (neat): 2966, 1708, 1601, 1466, 1336, 1262, 1156, 1095, 1037, 904, 758 cm⁻¹.




¹H NMR (500 MHz, CDCl₃): δ 7.63 (d, J = 8.0 Hz, 2H), 7.30 (t, J = 7.5 Hz, 1H), 7.22 (t, J = 7.5 Hz, 2H), 7.16 (d, J = 16.0 Hz, 1H), 7.01 (d, J = 8.0 Hz, 2H), 6.80 (d, J = 7.0 Hz, 2H), 5.79 (d, J = 16.0 Hz, 1H), 4.73 (d, J = 18.5 Hz, 1H), 4.54 (dd, J = 12.0, 5.0 Hz, 1H), 4.24-4.08 (m, 4H), 4.04 (d, J = 18.5 Hz, 1H), 2.15 (s, 3H), 1.93-1.84 (m, 1H), 1.25 (t, J = 7.0 Hz, 3H), 1.15 (d, J = 7.0 Hz, 3H), 1.02 (d, J = 7.0 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 167.5 (C), 164.9 (C), 143.6 (CH), 143.1 (C), 137.8 (C), 134.0 (C), 130.2 (2 × CH), 130.1 (CH), 129.4 (2 × CH), 127.7 (2 × CH), 127.3 (2 × CH), 113.7 (CH), 109.4 (C), 74.1 (CH₂), 63.4 (CH), 60.2 (CH₂), 41.1 (CH₂), 30.5 (CH), 21.3 (CH₃), 20.5 (CH₃), 19.3 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+Na⁺): m/z calcd. For C₂₆H₃₁NNaO₅S 492.1815, found 492.1819.

ethyl(S,E)-3-(3-benzyl-7-phenyl-4-tosyl-2,3,4,5-tetrahydro-1,4-oxazepin-6-yl)acrylate 3l:

To a magnetically stirred suspension of activated magnesium sulfate (0.633 gm, 5.25 mmol) and vinylogous carbonate **1l** (68.0 mg, 0.131 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (72 μL, 0.394 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel



column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3l** (36.0 mg, 53%).

Physical appearance: Sticky solid.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

[α]_D²⁵: -295.752 (c 0.455, CHCl₃).

IR (neat): 2922, 1701, 1601, 1587, 1366, 1262, 1156, 1044, 848, 756 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 7.64 (d, *J* = 8.5 Hz, 2H), 7.36-7.26 (m, 6H), 7.20 (t, *J* = 7.5 Hz, 2H), 7.15 (d, *J* = 16.0 Hz, 1H), 7.06 (d, *J* = 8.0 Hz, 2H), 6.82 (d, *J* = 7.5 Hz, 2H), 5.76 (d, *J* = 16.0 Hz, 1H), 4.71-4.65 (m, 2H), 4.26-4.18 (m, 2H), 4.14 (q, *J* = 7.0 Hz, 2H), 3.87 (d, *J* = 18.5 Hz, 1H), 3.15 (dd, *J* = 13.5, 3.5 Hz, 1H), 2.97 (dd, *J* = 13.5, 8.5 Hz, 1H), 2.20 (s, 3H), 1.26 (t, *J* = 7.5 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 167.5 (C), 164.6 (C), 143.7 (CH), 143.3 (C), 137.7 (C), 136.5 (C), 134.1 (C), 130.2 (3 × CH), 129.6 (2 × CH), 129.5 (2 × CH), 128.9 (2 × CH), 127.8 (2 × CH), 127.2 (CH), 127.1 (2 × CH), 113.5 (CH), 109.2 (C), 73.3 (CH₂), 60.3 (CH₂), 58.9 (CH), 40.7 (CH₂), 39.2 (CH₂), 21.4 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₃₀H₃₂NO₅S 518.2000, found 518.2000.

ethyl(S,E)-3-(3-phenyl-7-(*p*-tolyl)-4-tosyl-2,3,4,5-tetrahydro-1,4-oxazepin-6-yl)acrylate 3m:

To a magnetically stirred suspension of activated magnesium sulfate (0.484 gm, 4.016 mmol) and vinylogous carbonate **1m** (52.0 mg, 0.100 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (55 μL, 0.301 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3m** (29.0 mg, 56%).

Physical appearance: white solid.


M.P: 104-106 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

[α]_D²⁵: -305.288 (c 0.355, CHCl₃).

IR (neat): 2979, 2919, 1705, 1601, 1588, 1364, 1261,

1166, 1137, 1038, 759 cm⁻¹.



¹H NMR (500 MHz, CDCl₃): δ 7.69 (d, *J* = 8.0 Hz, 2H), 7.43-7.39 (m, 4H), 7.35-7.32 (m, 1H), 7.21 (d, *J* = 16.0 Hz, 1H), 7.08 (t, *J* = 7.5 Hz, 4H), 6.80 (d, *J* = 8.0 Hz, 2H), 5.80 (d, *J* = 16.0 Hz, 1H), 5.65 (dd, *J* = 12.0, 6.0 Hz, 1H), 4.90 (d, *J* = 19.0 Hz, 1H), 4.71 (dd, *J* = 12.5, 6.0 Hz, 1H), 4.41 (t, *J* = 12.5 Hz, 1H), 4.23 (d, *J* = 18.5 Hz, 1H), 4.15 (q, *J* = 7.5 Hz, 2H), 2.35 (s, 3H), 2.23 (s, 3H), 1.26 (t, *J* = 7.5 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 167.5 (C), 165.0 (C), 143.8 (CH), 143.4 (C), 140.6 (C), 137.6 (C), 136.8 (C), 131.1 (C), 130.2 (2 × CH), 129.6 (2 × CH), 129.2 (2 × CH), 128.6 (2 × CH), 128.3 (CH), 127.2 (2 × CH), 126.1 (2 × CH), 113.3 (CH), 108.9 (C), 74.0 (CH₂), 60.8 (CH), 60.2 (CH₂), 41.5 (CH₂), 21.5 (CH₃), 21.4 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+Na⁺): m/z calcd. For C₃₀H₃₁NaNO₅S 540.1815, found 540.1818.


ethyl(E)-3-((4aR*,8aS*)-2-phenyl-4a,5,6,7,8,8a-hexahydro-4H-chromen-3-yl)acrylate 6a:

To a magnetically stirred suspension of activated magnesium sulfate (0.709 gm, 5.88 mmol) and vinylogous carbonate **5a** (46.0 mg, 0.147 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (81 μL, 0.442 mmol) was added dropwise at 0 °C. Reaction was monitored by TLC, quenched with saturated aq. solution of NaHCO₃ upon completion, extracted with CH₂Cl₂ (3 × 5 mL) and dried over anhydrous Na₂SO₄. Evaporation of the solvent and purification of the residue over a silica gel column using EtOAc-petroleum ether as eluent furnished the dihydropyran **6a** (37.0 mg, 80%).

Physical appearance: White solid.

M.P: 82-84 °C.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).



IR (neat): 2931, 2858, 1710, 1605, 1592, 1364, 1242, 1151, 1017, 699 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 7.56 (d, J = 15.5 Hz, 1H), 7.42-7.38 (m, 5H), 5.68 (d, J = 15.0 Hz, 1H), 4.14 (q, J = 7.0 Hz, 2H), 3.65 (td, J = 10.0, 4.0 Hz, 1H), 2.41 (dd, J = 16.5, 5.5 Hz, 1H), 2.18 (dd, J = 9.5, 5.5 Hz, 1H), 2.01 (d, J = 13.0 Hz, 1H), 1.90-1.85 (m, 2H) 1.75 (d, J = 13.0 Hz, 1H), 1.71-1.62 (m, 1H), 1.47-1.28 (m, 3H), 1.24 (t, J = 7.0 Hz, 3H), 1.14-1.05 (m, 1H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 168.1 (C), 160.6 (C), 145.2 (CH), 134.9 (C), 130.0 (2 × CH), 129.5 (CH), 128.3 (2 × CH), 111.8 (CH), 108.7 (C), 80.2 (CH), 59.9 (CH₂), 36.9 (CH), 31.9 (CH₂), 31.8 (CH₂), 29.1 (CH₂), 25.5 (CH₂), 24.7 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₀H₂₅O₃ 313.1829, found 313.1829.

ethyl(E)-3-((4aR*,8aS*)-2-(p-tolyl)-4a,5,6,7,8,8a-hexahydro-4H-chromen-3-yl)acrylate 6b:


To a magnetically stirred suspension of activated magnesium sulfate (1.27 gm, 10.538 mmol) and vinylogous carbonate **5b** (86.0 mg, 0.263 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (143.0 μL, 0.790 mmol) was added dropwise at 0 °C as described for the

dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6b** (60.0 mg, 70%).

Physical appearance: sticky solid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2930, 1738, 1594, 1243, 1152, 1040, 760 cm⁻¹.



¹H NMR (400 MHz, CDCl₃): δ 7.60 (d, *J* = 15.6 Hz, 1H), 7.31 (d, *J* = 8.0 Hz, 2H), 7.19 (d, *J* = 8.4 Hz, 2H), 5.70 (d, *J* = 15.2 Hz, 1H), 4.14 (q, *J* = 7.2 Hz, 2H), 3.65-3.59 (m, 1H), 2.42-2.37 (m, 4H), 2.19-2.17 (m, 1H), 1.99 (d, *J* = 13.2 Hz, 1H), 1.89-1.82 (m, 2H), 1.74-1.59 (m, 2H), 1.49-1.28 (m, 3H), 1.24 (t, *J* = 7.2 Hz, 3H), 1.12-1.02 (m, 1H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 168.0 (C), 160.7 (C), 145.4 (CH), 139.5 (C), 131.9 (C), 129.8 (2 × CH), 128.9 (2 × CH), 111.3 (CH), 108.2 (C), 79.9 (CH), 59.7 (CH₂), 36.8 (CH), 31.8 (CH₂), 31.7 (CH₂), 29.0 (CH₂), 25.4 (CH₂), 24.6 (CH₂), 21.4 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₁H₂₇O₃ 327.1965, found 327.1964.


ethyl(E)-3-((4aR*,8aS*)-2-(4-methoxyphenyl)-4a,5,6,7,8a-hexahydro-4H-chromen-3-yl)acrylate 6c:

To a magnetically stirred suspension of activated magnesium sulfate (1.4 gm, 11.213 mmol) and vinylogous carbonate **5c** (96.0 mg, 0.280 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (152 μL, 0.841 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6c** (36.0 mg, 38%).

Physical appearance: Yellow liquid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2932, 1706, 1605, 1282, 1252, 1151, 1038, 835 cm⁻¹.



¹H NMR (500 MHz, CDCl₃): δ 7.59 (d, *J* = 15.5 Hz, 1H), 7.34 (d, *J* = 9.0 Hz, 2H), 6.90 (d, *J* = 8.5 Hz, 2H), 5.65 (d, *J* = 15.5 Hz, 1H), 4.14 (q, *J* = 7.0 Hz, 2H), 3.82 (s, 3H), 3.64-3.59 (m, 1H), 2.39 (dd, *J* = 16.0, 5.5 Hz, 1H), 2.17 (d, *J* = 10.0 Hz, 1H), 1.99 (d, *J* = 12.5 Hz, 1H), 1.87-1.81 (m, 2H), 1.73 (d, *J* = 12.5 Hz, 1H), 1.66-1.62 (m, 1H), 1.48-1.30 (m, 3H), 1.24 (t, *J* = 7.0 Hz, 3H), 1.11-1.04 (m, 1H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 168.2 (C), 160.6 (C), 160.5 (C), 145.6 (CH), 131.4 (2 × CH), 127.3 (C), 113.7 (2 × CH), 111.2 (CH), 108.0 (C), 80.0 (CH), 59.8

(CH₂), 55.4 (CH₃), 36.9 (CH), 31.9 (CH₂), 31.8 (CH₂), 29.2 (CH₂), 25.4 (CH₂), 24.7 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₁H₂₇O₄ 343.1929, found 343.1929.


ethyl(E)-3-((4aR*,8aS*)-2-(3-methoxyphenyl)-4a,5,6,7,8,8a-hexahydro-4H-chromen-3-yl)acrylate 6d:

To a magnetically stirred suspension of activated magnesium sulfate (913 mg, 7.592 mmol) and vinylogous carbonate **5d** (65.0 mg, 0.189 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (103 μ L, 0.569 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6d** (29.0 mg, 45%).

Physical appearance: Pale yellow liquid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2937, 1706, 1605, 1591, 1288, 1152, 1044, 759 cm⁻¹.




¹H NMR (500 MHz, CDCl₃): δ 7.59 (d, *J* = 15.5 Hz, 1H), 7.29 (t, *J* = 8.0 Hz, 1H), 6.99 (d, *J* = 7.5 Hz, 1H), 6.93 (d, *J* = 9.0 Hz, 2H), 5.67 (d, *J* = 15.5 Hz, 1H), 4.14 (q, *J* = 7.0 Hz, 2H), 3.81 (s, 3H), 3.66-3.61 (m, 1H), 2.40 (dd, *J* = 16.0, 5.5 Hz, 1H), 2.18 (d, *J* = 10.0 Hz, 1H), 2.00 (d, *J* = 13.0 Hz, 1H), 1.89-1.84 (m, 2H), 1.74 (d, *J* = 13.0 Hz, 1H), 1.70-1.62 (m, 1H), 1.49-1.29 (m, 3H), 1.24 (t, *J* = 7.0 Hz, 3H), 1.12-1.05 (m, 1H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 168.0 (C), 160.2 (C), 159.4 (C), 145.1 (CH), 136.1 (C), 129.2 (CH), 122.6 (CH), 115.5 (CH), 115.1 (CH), 111.9 (CH), 108.7 (C), 80.2 (CH), 59.9 (CH₂), 55.4 (CH₃), 36.8 (CH), 31.9 (CH₂), 31.8 (CH₂), 29.1 (CH₂), 25.4 (CH₂), 24.7 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₁H₂₇O₄ 343.1931, found 343.1930.

ethyl(E)-3-((4aR*,8aS*)-2-(4-chlorophenyl)-4a,5,6,7,8,8a-hexahydro-4H-chromen-3-yl)acrylate 6e:

To a magnetically stirred suspension of activated magnesium sulfate (0.869 gm, 7.150 mmol) and vinylogous carbonate **5e** (62.0 mg, 0.178 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (97 μ L, 0.536 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6e** (42.0 mg, 69%).



Physical appearance: White solid.

M.P: 83-85 °C.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2933, 1707, 1606, 1242, 1153, 1044, 834, 759 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.49 (d, *J* = 15.2 Hz, 1H), 7.37-7.33 (m, 4H), 5.69 (d, *J* = 15.6 Hz, 1H), 4.14 (q, *J* = 7.2 Hz, 2H), 3.65-3.59 (m, 1H), 2.39 (dd, *J* = 16.4, 5.6 Hz, 1H), 2.18-2.16 (m, 1H), 2.00 (d, *J* = 12.8 Hz, 1H), 1.89-1.82 (m, 2H), 1.75-1.59 (m, 2H), 1.48-1.28 (m, 3H), 1.24 (t, *J* = 6.8 Hz, 3H), 1.13-1.03 (m, 1H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.9 (C), 159.1 (C), 144.5 (CH), 135.5 (C), 133.3 (C), 131.2 (2 × CH), 128.5 (2 × CH), 112.4 (CH), 109.1 (C), 80.2 (CH), 60.0 (CH₂), 36.8 (CH), 31.8 (CH₂), 31.7 (CH₂), 29.0 (CH₂), 25.4 (CH₂), 24.6 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₀H₂₄ClO₃ 347.1445, found 347.1445.

ethyl(E)-3-((4aR*,8aS*)-2-(4-bromophenyl)-4a,5,6,7,8a-hexahydro-4H-chromen-3-yl)acrylate 6f:


To a magnetically stirred suspension of activated magnesium sulfate (0.678 gm, 5.622 mmol) and vinylogous carbonate **5f** (55.0 mg, 0.140 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (77 μL, 0.421 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6f** (40.0 mg, 73%).

Physical appearance: Yellow Solid.

M.P: 97-100 °C.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2931, 1708, 1603, 1243, 1176, 1153, 706 cm⁻¹.



¹H NMR (400 MHz, CDCl₃): δ 7.52-7.47 (m, 3H), 7.29-7.27 (m, 2H), 5.69 (d, *J* = 15.6 Hz, 1H), 4.14 (q, *J* = 7.2 Hz, 2H), 3.65-3.59 (m, 1H), 2.39 (dd, *J* = 16.4, 5.6 Hz, 1H), 2.18-2.16 (m, 1H), 2.01-1.98 (m, 1H), 1.88-1.81 (m, 2H), 1.75-1.60 (m, 2H), 1.45-1.28 (m, 3H), 1.24 (t, *J* = 7.2 Hz, 3H), 1.13-1.03 (m, 1H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.9 (C), 159.1 (C), 144.4 (CH), 133.7 (C), 131.5 (4 × CH), 123.8 (C), 112.5 (CH), 109.1 (C), 80.2 (CH), 60.0 (CH₂), 36.8 (CH), 31.8 (CH₂), 31.7 (CH₂), 29.0 (CH₂), 25.4 (CH₂), 24.6 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₀H₂₄BrO₃ 391.0929, found 391.0928.


(Note: Compound 6g shows rotamers and data written for the major isomer.)

ethyl(E)-3-((4aR,8aS*)-2-(2-bromophenyl)-4a,5,6,7,8,8a-hexahydro-4H-chromen-3-yl)acrylate 6g:*

To a magnetically stirred suspension of activated magnesium sulfate (1.0gm, 8.791 mmol) and vinylogous carbonate **5g** (86.0 mg, 0.219 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (120.0 μ L, 0.659 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6g** (38.0 mg, 44%).

Physical appearance: Yellow liquid.

R_f: 0.5 (1.5:8.5, EtOAc: Petroleum ether).



IR (neat): 2930, 1713, 1601, 1466, 1230, 1113, 1001, 773 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.60 (t, *J* = 7.6 Hz, 1H), 7.34-7.22 (m, 3H), 7.13 (d, *J* = 15.2 Hz, 1H), 5.67 (d, *J* = 15.6 Hz, 1H), 4.10 (q, *J* = 6.8 Hz, 2H) 3.70 (dt, *J* = 10.4, 4.4 Hz, 1H), 2.37 (dd, *J* = 16.4, 5.2 Hz, 1H), 2.15-2.12 (m, 1H), 2.02-1.86 (m, 3H), 1.76-1.68 (m, 2H), 1.43-1.25 (m, 3H), 1.22 (t, *J* = 7.2 Hz, 3H), 1.16-1.07 (m, 1H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.8 (C), 159.6 (C), 143.9 (CH), 135.7 (C), 133.3 (CH), 132.1 (CH), 130.7 (CH), 127.2 (CH), 124.1 (C), 112.4 (CH), 110.6 (C), 80.1 (CH), 60.0 (CH₂), 36.7 (CH), 32.0 (CH₂), 31.6 (CH₂), 28.5 (CH₂), 25.5 (CH₂), 24.8 (CH₂), 14.4 (CH₃).


HRMS (ESI, M+H⁺): m/z calcd. For C₂₀H₂₄BrO₃ 391.0925, found 391.0924.

ethyl(E)-3-((4aR,8aS*)-2-(4-nitrophenyl)-4a,5,6,7,8,8a-hexahydro-4H-chromen-3-yl)acrylate 6h:*

To a magnetically stirred suspension of activated magnesium sulfate (1.6 gm, 13.215 mmol) and vinylogous carbonate **5h** (118.0 mg, 0.330 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (180 μ L, 0.991 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6h** (71.0 mg, 60%).

Physical appearance: Yellow solid.

M.P: 118-120 °C.



R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2936, 1706, 1607, 1522, 1347, 1244, 1154, 1039, 759 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 8.22 (d, *J* = 8.8 Hz, 2H), 7.57 (d, *J* = 8.4 Hz, 2H), 7.41 (d, *J* = 15.6 Hz, 1H), 5.75 (d, *J* = 15.2 Hz, 1H), 4.12 (q, *J* = 7.2 Hz, 2H), 3.67-

3.62 (m, 1H), 2.42 (dd, $J = 16.4, 5.2$ Hz, 1H), 2.17 (d, $J = 8.0$ Hz, 1H), 2.00 (d, $J = 12.8$ Hz, 1H), 1.92-1.85 (m, 2H), 1.73 (d, $J = 12.8$ Hz, 1H), 1.67-1.64 (m, 1H), 1.44-1.29 (m, 3H), 1.22 (t, $J = 7.2$ Hz, 3H), 1.13-1.04 (m, 1H).

^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 167.5 (C), 157.3 (C), 148.0 (C), 143.2 (CH), 141.0 (C), 130.8 (2 \times CH), 123.4 (2 \times CH), 113.9 (CH), 110.8 (C), 80.4 (CH), 60.1 (CH₂), 36.7 (CH), 31.7 (CH₂), 31.6 (CH₂), 29.0 (CH₂), 25.3 (CH₂), 24.6 (CH₂), 14.4 (CH₃).


HRMS (ESI, M+ H⁺): m/z calcd. For $\text{C}_{20}\text{H}_{24}\text{NO}_5$ 358.1658, found 358.1657.

ethyl(E)-3-((4aR*,7aS*)-2-(*p*-tolyl)-4,4a,5,6,7,7a-hexahydrocyclopenta[b]pyran-3-yl)acrylate 6i:

To a magnetically stirred suspension of activated magnesium sulfate (1.20 gm, 9.730 mmol) and vinylogous carbonate **5i** (76.0 mg, 0.243 mmol) in dry CH_2Cl_2 (5 mL), TMSOTf (133 μL , 0.729 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6i** (40.0 mg, 53%).

Physical appearance: Yellow sticky solid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).



IR (neat): 2950, 1711, 1605, 1582, 1310, 1244, 1176, 1037, 829, 756 cm⁻¹.

^1H NMR (500 MHz, CDCl_3): δ 7.60 (d, $J = 15.5$ Hz, 1H), 7.31 (d, $J = 8.0$ Hz, 2H), 7.19 (d, $J = 8.0$ Hz, 2H), 5.71 (d, $J = 15.5$ Hz, 1H), 4.14 (q, $J = 7.2$ Hz, 2H), 3.82-3.76 (m, 1H), 2.59 (dd, $J = 15.5, 5.5$ Hz, 1H), 2.37 (s, 3H), 2.32-2.27 (m, 1H), 2.18-2.12 (m, 1H), 2.08-2.00 (m, 2H), 1.92-1.79 (m, 2H), 1.75-1.67 (m, 2H), 1.25 (t, $J = 7.5$ Hz, 3H).

^{13}C NMR (125 MHz, CDCl_3 , DEPT): δ 168.0 (C), 162.0 (C), 145.8 (CH), 139.6 (C), 132.1 (C), 130.0 (2 \times CH), 128.9 (2 \times CH), 111.7 (CH), 109.2 (C), 82.6 (CH), 59.8 (CH₂), 39.6 (CH), 29.2 (CH₂), 28.4 (CH₂), 27.6 (CH₂), 21.4 (CH₃), 20.0 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For $\text{C}_{20}\text{H}_{25}\text{O}_3$ 313.1828, found 313.1827.


ethyl(E)-3-(2-methyl-6-phenyl-3,4-dihydro-2H-pyran-5-yl)acrylate 6j:

To a magnetically stirred suspension of activated magnesium sulfate (1.44 gm, 12.04 mmol) and vinylogous carbonate **5j** (82.0 mg, 0.301 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (165 μ L, 0.903 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6j** (42.0 mg, 51%).

Physical appearance: White solid.

M.P: 65-67 °C.

R_f: 0.5 (1.5:8.5, EtOAc: Petroleum ether).



IR (neat): 2931, 1708, 1605, 1592, 1265, 1247, 1039, 768, 699 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 7.58 (d, *J* = 15.2 Hz, 1H), 7.43-7.38 (m, 5H), 5.69 (d, *J* = 15.6 Hz, 1H), 4.24-4.10 (m, 3H), 2.42-2.25 (m, 2H), 2.08-2.02 (m, 1H), 1.78-1.67 (m, 1H), 1.40 (d, *J* = 6.0 Hz, 3H), 1.24 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 168.0 (C), 160.7 (C), 145.2 (CH), 135.0 (C), 129.9 (2 \times CH), 129.5 (CH) 128.2 (2 \times CH), 111.8 (CH), 108.3 (C), 73.4 (CH), 59.9 (CH₂), 28.9 (CH₂), 21.5 (CH₂), 20.8 (CH₃), 14.5 (CH₃).


HRMS (ESI, M+ H⁺): m/z calcd. For C₁₇H₂₁O₃ 273.1502, found 287. 273.1501.

ethyl (E)-3-(2-methyl-6-(*p*-tolyl)-3,4-dihydro-2H-pyran-5-yl)acrylate 6k:

To a magnetically stirred suspension of activated magnesium sulfate (1.7gm, 13.967 mmol) and vinylogous carbonate **5k** (100.0 mg, 0.349 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (190 μ L, 1.047 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6k** (60.0 mg, 60%).

Physical appearance: Yellow liquid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).



IR (neat): 2955, 1707, 1596, 1268, 1177, 758 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 7.61 (d, *J* = 15.5 Hz, 1H), 7.31 (d, *J* = 8.0 Hz, 2H), 7.19 (d, *J* = 7.5 Hz, 2H), 5.67 (d, *J* = 15.5 Hz, 1H), 4.17-4.13 (m, 3H), 2.39-2.35 (m, 4H), 2.31-2.24 (m, 1H), 2.05-2.01 (m, 1H), 1.74-1.66 (m, 1H), 1.39 (d, *J* = 6.5 Hz, 3H), 1.25 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 168.0 (C), 160.8 (C), 145.4 (CH), 139.5 (C), 132.0 (C), 129.8 (2 \times CH), 128.8 (2 \times CH), 111.3 (CH), 107.9 (C), 73.3 (CH), 59.8 (CH₂), 28.8 (CH₂), 21.5 (CH₂), 21.4 (CH₃), 20.8 (CH₃), 14.4 (CH₃).


HRMS (ESI, M+ H⁺): m/z calcd. For C₁₈H₂₃O₃ 287.1669, found 287.1669.

ethyl(E)-3-(2-((benzyloxy)methyl)-6-(p-tolyl)-3,4-dihydro-2H-pyran-5-yl)acrylate 6l:

To a magnetically stirred suspension of activated magnesium sulfate (980 mg, 8.153 mmol) and vinylogous carbonate **5l** (80.0 mg, 0.203 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (110 µL, 0.611 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6l** (51.0 mg, 64%).

Physical appearance: sticky solid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).



IR (neat): 2919, 2741, 1725, 1713, 1601, 1268, 1124, 717 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 7.62 (d, *J* = 15.5 Hz, 1H), 7.36-7.28 (m, 7H), 7.21 (d, *J* = 8.0 Hz, 2H), 5.70 (d, *J* = 15.5 Hz, 1H), 4.61 (d, *J* = 2.0 Hz, 2H), 4.27-4.21 (m, 1H), 4.16 (q, *J* = 7.0 Hz, 2H), 3.74 (dd, *J* = 10.0, 5.5 Hz, 1H), 3.66 (dd, *J* = 10.0, 5.0 Hz, 1H), 2.43-2.27 (m, 5H), 2.13-2.10 (m, 1H), 1.88-1.80 (m, 1H), 1.26 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃, DEPT): δ 168.0 (C), 160.4 (C), 145.2 (CH), 139.6 (C), 138.1 (C), 131.8 (C), 129.9 (2 × CH), 128.9 (2 × CH), 128.5 (2 × CH), 127.8 (CH), 127.7 (2 × CH), 111.8 (CH), 108.3 (C), 76.0 (CH), 73.6 (CH₂), 72.0 (CH₂), 59.9 (CH₂), 24.2 (CH₂), 21.4 (CH₃), 21.1 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₅H₂₉O₄ 393.2064, found 393.2064.

ethyl(E)-3-(2-(chloromethyl)-6-(p-tolyl)-3,4-dihydro-2H-pyran-5-yl)acrylate 6m:

To a magnetically stirred suspension of activated magnesium sulfate (1.0 gm, 8.727 mmol) and vinylogous carbonate **5m** (70.0 mg, 0.218 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (119 µL, 0.654 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6m** (40.0 mg, 57%).



Physical appearance: sticky solid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2939, 1705, 1605, 1313, 1268, 1177, 1045, 821, 758 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, *J* = 15.6 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 5.70 (d, *J* = 15.6 Hz, 1H), 4.24-4.20 (m, 1H), 4.15 (q, *J* = 6.8


Hz, 2H), 3.74 (dd, J = 12.8, 6.0 Hz, 1H), 3.65 (dd, J = 11.2, 5.2 Hz, 1H), 2.46-2.27 (m, 5H), 2.20-2.15 (m, 1H), 1.91-1.81 (m, 1H), 1.25 (t, J = 7.2 Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 167.8 (C), 159.7 (C), 144.7 (CH), 139.9 (C), 131.4 (C), 129.9 (2 \times CH), 129.0 (2 \times CH), 112.4 (CH), 108.3 (C), 76.1 (CH), 60.0 (CH₂), 45.6 (CH₂), 24.8 (CH₂), 21.5 (CH₃), 20.9 (CH₂), 14.4 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For $\text{C}_{18}\text{H}_{22}\text{ClO}_3$ 321.1254, found 321.1254.

ethyl(E)-3-(3-phenyl-6-(p-tolyl)-3,4-dihydro-2H-pyran-5-yl)acrylate 6n:

To a magnetically stirred suspension of activated magnesium sulfate (1.3 gm, 10.905 mmol) and vinylogous carbonate **5n** (95.0 mg, 0.272 mmol) in dry CH_2Cl_2 (5 mL), TMSOTf (148 μL , 0.817 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6n** (58.0 mg, 61%).



Physical appearance: Pale yellow solid.

M.P: 80-82 °C.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2966, 1706, 1606, 1598, 1253, 1175, 826, 678 cm^{-1} .


^1H NMR (400 MHz, CDCl_3): δ 7.66 (d, J = 15.6 Hz, 1H), 7.40-7.22 (m, 9H), 5.72 (d, J = 15.6 Hz, 1H), 4.44-4.40 (m, 1H), 4.16 (q, J = 7.2 Hz, 2H), 4.08 (t, J = 10.4 Hz, 1H), 3.29-3.22 (m, 1H), 2.71 (dd, J = 16.4, 4.4 Hz, 1H), 2.50 (dd, J = 16.8, 10.8 Hz, 1H), 2.40 (s, 3H), 1.25 (t, J = 6.8 Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 168.0 (C), 160.5 (C), 145.0 (CH), 141.2 (C), 139.8 (C), 131.6 (C), 129.8 (2 \times CH), 129.0 (2 \times CH), 128.9 (2 \times CH), 127.5 (2 \times CH), 127.3 (CH), 112.1 (CH), 108.5 (C), 71.4 (CH₂), 59.9 (CH₂), 38.6 (CH), 29.3 (CH₂), 21.5 (CH₃), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For $\text{C}_{23}\text{H}_{25}\text{O}_3$ 349.1801, found 349.1801.

ethyl(E)-3-(2-ethynyl-6-(p-tolyl)-3,4-dihydro-2H-pyran-5-yl)acrylate 6o:

To a magnetically stirred suspension of activated magnesium sulfate (910 mg, 7.55 mmol) and vinylogous carbonate **5o** (56.0 mg, 0.188 mmol) in dry CH_2Cl_2 (5 mL), TMSOTf (102 μL , 0.566 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel



column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6o** (25.0 mg, 47%).

Physical appearance: Yellow liquid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 3021, 3003, 2344, 1685, 1606, 1251, 1216, 1044, 759, 669 cm⁻¹.


¹H NMR (400 MHz, CDCl₃): δ 7.56 (d, *J* = 15.6 Hz, 1H), 7.30 (dd, *J* = 6.4, 1.6 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 5.72 (d, *J* = 15.6 Hz, 1H), 4.96-4.93 (m, 1H), 4.15 (q, *J* = 7.2 Hz, 2H), 2.52-2.44 (m, 2H), 2.40-2.31 (m, 4H), 2.25-2.19 (m, 1H), 2.18-2.10 (m, 1H), 1.25 (t, *J* = 6.8 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.9 (C), 158.9 (C), 144.8 (CH), 139.8 (C), 131.5 (C), 129.9 (2 × CH), 129.0 (2 × CH), 112.7 (CH), 108.6 (C), 81.1(C), 74.0 (CH), 65.9 (CH), 60.0 (CH₂), 27.4 (CH₂), 21.5 (CH₃), 19.6 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₁₉H₂₁O₃ 297.1487, found 297.1486.

ethyl(E)-3-(2-(prop-2-yn-1-yl)-6-(p-tolyl)-3,4-dihydro-2H-pyran-5-yl)acrylate 6p:

To a magnetically stirred suspension of activated magnesium sulfate (1.56 gm, 13.01 mmol) and vinylogous carbonate **5p** (101.0 mg, 0.325 mmol) in dry CH₂Cl₂ (5 mL), TMSOTf (176 μL, 0.976 mmol) was added dropwise at 0 °C as described for the dihydropyran **6a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the dihydropyran **6p** (38.0 mg, 38%).



Physical appearance: sticky solid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 3278, 2932, 2344, 1705, 1605, 1312, 1177, 759 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, *J* = 15.6 Hz, 1H), 7.31 (d, *J* = 8.4, Hz, 2H), 7.19 (d, *J* = 8.0 Hz, 2H), 5.70 (d, *J* = 15.2 Hz, 1H), 4.21-4.12 (m, 3H), 2.70 (abxm, *J* = 16.8, 5.6, 2.8 Hz, 1H), 2.53 (abxm, *J* = 16.8, 7.2, 2.4 Hz, 1H), 2.45-2.21 (m, 6H), 2.06 (t, *J* = 2.8 Hz, 1H), 1.89-1.80 (m, 1H), 1.25 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.9 (C), 160.1 (C), 145.0 (CH), 139.7 (C), 131.7 (C), 129.9 (2 × CH), 128.9 (2 × CH), 112.1 (CH), 108.3 (C), 79.8 (C), 74.8 (CH), 70.8 (CH), 59.9 (CH₂), 26.1 (CH₂), 24.7 (CH₂), 21.5 (CH₃), 21.1 (CH₂), 14.5 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₀H₂₃O₃ 311.1664, found 311.1663.

ethyl(S,E)-3-(3-isobutyl-7-(*p*-tolyl)-4-tosyl-2,3,4,5-tetrahydro-1,4-oxazepin-6-yl)acrylate 3i (gram scale synthesis):


To a magnetically stirred suspension of activated magnesium sulfate (9.771 gm, 81.181 mmol) and vinylogous carbonate **1i** (1.01 gm, 0.341 mmol) in dry CH₂Cl₂ (30 mL), TMSOTf (1.10 mL, 6.088 mmol) was added dropwise at 0 °C as described for the 1,4-oxazepine **3a** followed by purification on a silica gel column using ethyl acetate-petroleum ether as eluent furnished the 1,4-oxazepine **3i** (430.0 mg, 43%).

Physical appearance: Pale yellow solid.

M.P: 80-82 °C.

R_f: 0.5 (3:7, EtOAc: Petroleum ether).

[α]_D²⁵: -507.720 (c 0.605, CHCl₃).



IR (neat): 2955, 1708, 1601, 1466, 1311, 1261, 1174, 1095, 1037, 824, 670 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 16.0 Hz, 1H), 7.05-7.00 (m, 4H), 6.73 (d, *J* = 6.8 Hz, 2H), 5.77 (d, *J* = 16.0 Hz, 1H), 4.67 (d, *J* = 18.8 Hz, 1H), 4.56-4.48 (m, 1H), 4.33 (dd, *J* = 12.4, 5.6 Hz, 1H), 4.14 (q, *J* = 7.2 Hz, 2H), 4.04 (d, *J* = 18.8 Hz, 1H), 3.99 (t, *J* = 12.0 Hz, 1H), 2.32 (s, 3H), 2.16 (s, 3H), 1.89-1.79 (m, 1H), 1.56-1.49 (m, 1H), 1.25 (t, *J* = 7.2 Hz, 4H), 1.01 (d, *J* = 6.4 Hz, 3H), 1.00 (d, *J* = 6.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 167.5 (C), 165.2 (C), 143.9 (CH), 143.0 (C), 140.4 (C), 137.7 (C), 131.1 (C), 130.1 (2 × CH), 129.4 (2 × CH), 128.4 (2 × CH), 127.2 (2 × CH), 113.1 (CH), 109.0 (C), 74.7 (CH₂), 60.1 (CH₂), 56.2 (CH), 40.1 (CH₂), 40.0 (CH₂), 24.7 (CH), 23.0 (CH₃), 22.7 (CH₃), 21.4 (CH₃), 21.3 (CH₃), 14.4 (CH₃).

HRMS (ESI, M+ H⁺): m/z calcd. For C₂₈H₃₆NO₅S 498.2342, found 498.2341.


*ethyl 3-((2*S**,3*S**,4*a**R**,8*a**S**)-2-(*p*-tolyl)octahydro-2*H*-chromen-3-yl)propanoate 7:*

To a magnetically stirred solution of dihydropyran **6b** (50.0 mg, 0.153 mmol) and Et₃SiH (74.0 µL, 0.459 mmol) in dry CH₂Cl₂ (3 mL), TMSOTf (28 µL, 0.153 mmol) was added dropwise at 0 °C. Reaction was monitored by TLC, quenched with saturated aq. solution of NaHCO₃ extracted with CH₂Cl₂ (3 × 5 mL) and dried over anhydrous Na₂SO₄. Evaporation of the solvent and purification of the residue over a silica gel column using ethyl acetate petroleum ether as eluent furnished dihydropyran derivative **7** (47.0 mg, 93%).

Physical appearance: Yellow liquid.

R_f: 0.6 (1:9, EtOAc: Petroleum ether).

IR (neat): 2927, 1735, 1449, 1336, 1241, 1164, 1091, 1060, 967, 778 cm⁻¹.




¹H NMR (400 MHz, CDCl₃): δ 7.18 (d, *J* = 8.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 4.63 (d, *J* = 1.2 Hz, 1H), 4.05 (q, *J* = 7.2 Hz, 2H), 3.10 (td, *J* = 10.0, 3.6 Hz, 1H), 2.32 (s, 3H), 2.16-2.19 (m, 1H), 1.98-1.23 (m, 14H), 1.19 (t, *J* = 7.2 Hz, 3H), 1.05-0.95 (m, 1H).

¹³C NMR (100 MHz, CDCl₃, DEPT): δ 173.9 (C), 138.7 (C), 136.0 (C), 128.8 (2 × CH), 125.4 (2 × CH), 83.4 (CH), 81.6 (CH), 60.2 (CH₂), 39.2 (CH), 36.2 (CH), 34.8 (CH₂), 32.8 (CH₂), 32.5 (CH₂), 31.8 (CH₂), 26.0 (CH₂), 25.2 (CH₂), 21.3 (CH₂), 21.2 (CH₃), 14.3 (CH₃).

HRMS (ESI, M+Na⁺): m/z calcd. For C₂₁H₃₀NaO₃ 353.2087, found 353.2093.

*ethyl(Z)-2-((5*a**S**,9*a**R**)-6,7,8,9*a*,10-hexahydroindeno[1,2-*b*]chromen-11(5*a*H)-ylidene)acetate 8:*

To a well evacuated, magnetically stirred mixture of dihydropyran derivative **6g** (36.0 mg, 0.0897 mmol) was added Pd(OAc)₂ (4.0 mg, 0.016 mmol), PPh₃ (9.4 mg, 0.035 mmol) followed by dry acetonitrile (5 mL) and trimethylamine (50.0 µL, 0.358 mmol L) at room temperature. The colour of the solution turns yellow. This mixture was heated at 80 °C and the solution turns brownish black in half an hour. After *ca.*14 hr (TLC control), the reaction mixture was concentrated under reduced pressure. Purification of the residue over a silica gel column using EtOAc-petroleum ether as eluent furnished tetracyclic hydroindeno chromene derivative **8** (26.0 mg, 90%).



Physical appearance: Yellow liquid.


R_f: 0.6 (1:9, EtOAc: Petroleum ether).



IR (neat): 2929, 1716, 1595, 1573, 1446, 1169, 1154, 1002, 759 cm⁻¹

¹H NMR (400 MHz, CDCl₃): δ 7.43 (d, *J* = 7.6 Hz, 1H), 7.24 (t, *J* = 8.4 Hz, 1H), 7.20-7.14 (m, 2H), 6.32 (s, 1H), 4.24 (q, *J* = 6.8 Hz, 2H), 3.78 (td, *J* = 10.8, 4.4 Hz, 1H), 2.81 (dd, *J* = 17.2, 4.8 Hz, 1H), 2.38 (dd, *J* = 17.2, 10.8 Hz, 1H), 2.28 (dd, *J* = 7.2, 3.2 Hz, 1H), 2.01 (d, *J* = 13.2 Hz, 1H), 1.90 (d, *J* = 12.4 Hz, 1H), 1.74 (d, *J* = 12.8 Hz, 1H), 1.60-1.39 (m, 4H), 1.34 (t, *J* = 7.2 Hz, 3H), 1.20-1.10 (m, 1H).



¹³C NMR (100 MHz, CDCl₃, DEPT): δ 166.8 (C), 163.0 (C), 148.9 (C), 137.4 (C), 136.1 (C), 129.0 (CH), 126.8 (CH), 119.1 (CH), 117.2 (CH), 109.3 (CH), 108.7 (C), 81.3 (CH), 60.4 (CH₂), 38.0 (CH), 32.2 (2 × CH₂), 29.6 (CH₂), 25.8 (CH₂), 24.9 (CH₂), 14.5 (CH₃).


HRMS (ESI, M+Na⁺): m/z calcd. For C₂₀H₂₂NaO₃ 333.1461, found 333.1458.










— 143.58
 — 137.78
 — 131.57
 — 129.60
 — 128.77
 — 128.40
 — 127.69
 — 122.02
 — 84.88
 — 84.81
 — 77.48
 — 77.16
 — 76.44
 — 70.07
 — 64.43











































































































NOE, CDCl_3 , 400 MHz







HSQC, CDCl₃, 400 MHz






NOE, CDCl₃, 400 MHz



**X-Ray crystallographic analysis:
Crystal data and structure refinement for 3b:**



| | | | |
|------------------------|----------------------------|--------------------|-----------|
| Identification code | 3b | | |
| Solvent | CH_2Cl_2 | | |
| CCDC | 2181886 | | |
| Bond precision: | C-C = 0.0031 Å | Wavelength=0.71073 | |
| Cell: | a=11.7622 (4) | b=14.0804 (3) | c=16.2304 |
| (5) | alpha=90 | beta=105.570 (3) | gamma=90 |
| Temperature: | 150 K | | |
| | Calculated | Reported | |
| Volume | 2589.38 (14) | 2589.38 (14) | |
| Space group | P 21/n | P 1 21/n 1 | |
| Hall group | -P 2yn | -P 2yn | |
| Moiety formula | C28 H33 N O5 S [+ solvent] | C28 H33 N O5 S | |
| Sum formula | C28 H33 N O5 S [+ solvent] | C28 H33 N O5 S | |
| Mr | 495.61 | 495.61 | |
| Dx,g cm ⁻³ | 1.271 | 1.271 | |
| Z | 4 | 4 | |
| Mu (mm ⁻¹) | 0.163 | 0.163 | |
| F000 | 1056.0 | 1056.0 | |
| F000' | 1056.97 | | |
| h,k,lmax | 13,16,19 | 13,16,19 | |
| Nref | 4565 | 4561 | |
| Tmin,Tmax | 0.991,0.996 | 0.902,1.000 | |
| Tmin' | 0.931 | | |

Correction method= # Reported T Limits: Tmin=0.902 Tmax=1.000

AbsCorr = MULTI-SCAN

Data completeness= 0.999

Theta(max)= 24.999


R(reflections)= 0.0463(3604)

wR2(reflections)=
0.1255(4561)

S = 1.064

Npar= 320

Crystal data and structure refinement for 6j:



Identification code

6j

Solvent

CH_2Cl_2

CCDC

2181887

Bond precision:

C-C = 0.0031 Å

Wavelength=0.71073

Cell:

a=8.8310(4)

b=10.8732(4)

c=16.2743(9)

alpha=90

beta=103.292(5)

gamma=90

Temperature:

150 K

| | Calculated | Reported |
|------------------------|-------------|-------------|
| Volume | 1520.82(13) | 1520.82(13) |
| Space group | P 21/c | P 1 21/c 1 |
| Hall group | -P 2ybc | -P 2ybc |
| Moiety formula | C17 H20 O3 | C17 H20 O3 |
| Sum formula | C17 H20 O3 | C17 H20 O3 |
| Mr | 272.33 | 272.33 |
| Dx,g cm ⁻³ | 1.189 | 1.189 |
| Z | 4 | 4 |
| Mu (mm ⁻¹) | 0.080 | 0.080 |
| F000 | 584.0 | 584.0 |
| F000' | 584.29 | |
| h,k,lmax | 10,12,19 | 10,12,19 |
| Nref | 2682 | 2668 |
| Tmin,Tmax | 0.997,0.998 | 0.385,1.000 |
| Tmin' | 0.994 | |

Correction method= # Reported T Limits: Tmin=0.385 Tmax=1.000

AbsCorr = MULTI-SCAN

Data completeness= 0.995

Theta(max)= 25.000

R(reflections)= 0.0521(2181)

wR2(reflections)=

0.1420(2668)

S = 1.061

Npar= 184